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Purpose: A sacral chordoma is a rare, slow-growing, primary bone tumor, arising from embryonic notochordal remnants. 
Radical surgery is the only hope for cure. The aim of our present study is to analyse our experience with the challenging 
treatment of this rare tumor, to review current treatment modalities and to assess the outcome based on R status.
Methods: Eight patients were treated in our institution between 2001 and 2011. All patients were discussed by a multidis-
ciplinary tumor board, and an en bloc surgical resection by posterior perineal access only or by combined anterior/poste-
rior accesses was planned based on tumor extension. 
Results: Seven patients underwent radical surgery, and one was treated by using local cryotherapy alone due to low per-
formance status. Three misdiagnosed patients had primary surgery at another hospital with R1 margins. Reresection mar-
gins in our institution were R1 in two and R0 in one, and all three recurred. Four patients were primarily operated on at 
our institution and had en bloc surgery with R0 resection margins. One had local recurrence after 18 months. The overall 
morbidity rate was 86% (6/7 patients) and was mostly related to the perineal wound. Overall, 3 out of 7 resected patients 
were disease-free at a median follow-up of 2.9 years (range, 1.6–8.0 years).
Conclusion: Our experience confirms the importance of early correct diagnosis and of an R0 resection for a sacral chor-
doma invading pelvic structures. It is a rare disease that requires a challenging multidisciplinary treatment, which should 
ideally be performed in a tertiary referral center.
Keywords: Sacrum; Chordoma; perineum
INTRODUCTION
A chordoma is a rare, slow-growing, primary bone tumor arising 
from embryonic notochordal remnants. Chordomas constitute 
less than 5% of all primary bone neoplasms, tand heir incidence 
rate is 0.1/100,000. The most common localization is the sacrococ-
cygeal area (40%–50%) and the base of the skull (35%–40%), fol-
lowed by the vertebral bodies (15%–20%) [1, 2]. Sacrococcygeal 
chordomas usually require extensive composite resections includ-
ing the sacrum, the anorectum and the pelvi-perineal muscle.
Local recurrence (LR) after surgical treatment is common 
(43%–85%) even for an R0 resection [3, 4]. Distant disease is less 
frequent (20%–40%), but metastases to the bone, lung, liver, 
lymph-nodes and skin have been described [3-7]. The 10-year 
overall survival (OS) rate ranges from 30% to 65% [5, 7-12]. Radi-
cal surgery is the only hope for cure as no chemotherapy has been 
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demonstrated to be effective against a chordoma, and radiother-
apy is only marginally effective [5, 7, 9, 13-15]. The quality of the 
surgical margins achieved at primary surgery is the most impor-
tant factor for recovery, but is often limited by inadequate diagno-
sis prior to surgery. The aim of this study is to present our experi-
ence with the challenging treatment of this rare, often misdiag-
nosed tumor. This work reviews current treatment modalities and 
assesses outcomes based on R Status.
METHODS
The University Hospital of Lausanne is the tertiary referral center 
for a population of about 1 million inhabitants in South-Eastern 
Switzerland. Through a combination of diagnostic and surgical 
procedure codes, we identified all patients treated for sacral tu-
mours during the period from 2001 to 2011 in our academic in-
stitution. Charts were examined to identify patients with a diag-
nosis of sacral chordoma. We included patients who underwent 
primary surgery in our institution, surgery for LR after primary 
surgery performed elsewhere and patients who underwent pallia-
tive treatment. All patients had extensive pre-operative work-ups 
with computed tomography (CT) and magnetic resonance imag-
ing (MRI). The treatment strategy was discussed by a multidisci-
plinary tumor board for sarcomas based on our internal policy. 
According to tumor’s extension and resectability, the surgical ap-
proach was discussed, and en bloc resection was planned either by 
a posterior perineal approach only or by a combined anteroposte-
rior approach.
For the combined approach, the patient was first operated on in 
the supine position. Pelvic dissection was pursued down to the 
predefined sacrectomy level where a piece of gauze was left, an 
omental flap was prepared and positioned in the pelvis, the sig-
moid was transfected, an end-colostomy was fashioned, and the 
abdomen was closed. The patient was then turned and positioned 
prone with legs abducted. A perineal dissection with an en bloc 
sacrectomy was then completed. The defect was closed either 
with a combination of omentoplasty, absorbable mesh and direct 
wound closure or with temporary vacuum-assisted closure and 
secondary reconstruction with myocutaneous flaps for larger de-
fects. The resection status was considered R0 if surgical margins 
were ≥1 mm [16]. The special feature of our patients was the in-
volvement of pelvic visceral elements in all of them. Our institu-
tion has a dedicated surgical team specialized in sarcoma treat-
ment; the team includes oncologic surgeons and orthopedists 
working together with plastic and reconstructive surgeons.
RESULTS
Treatment and outcome
Eight patients were treated in our institution between 2001 and 
2011 for sacral chordoma. One patient unfit for surgery was 
treated by using local cryoablation with tumor palliative intent. 
The seven remaining patients underwent a curative surgical re-
section of the tumor (Table 1). Three (patients #1, #2, and #4) had 
had primary surgery in another hospital and were referred to our 
hospital after LR. The diagnosis was not suspected prior to the 
Table 1. Details of the patients and their outcomes
No
Age/
gender
Year
of Dx
Primary 
surgery
Bone
resection level
Muscle
resection level
Margins
/MDT
Local 
recurrence
Reoperation/
margins/MDT
Follow-up/
status
1 43/M 1998 PA/elsewhere S4 GM bil.
Piri. bil.
R1 Yes 24 mo PA/R1; CA/Rx 14 yr/AWD
2 58/F 2001 PA/elsewhere S4 GM bil. R1 Yes 24 mo PA/R1 11 yr/DOD
3 62/M 2004 PA S3 GM bil.
Piri. bil.
R0/0.2 cm No No 8 yr/AFD
4 40/M 2008 PA/elsewhere S5-coccyx GM bil. R1 Yes 11 mo CA/R0: 0.05 cm 4.7 yr/AWD
5 60/F 2010 CA S1–S2 Levator ani
Piri. bil.
GM bil.
R0/0.5 cm No No 2.9 yr/AFD
6 32/F 2011 CA S3 Levator ani
Piri bil.
GM bil.
Obturator intemus
R0/0.5 cm No No 1.6 yr/AFD
7 34/M 2011 CA S3 Levator ani
Piri. bil.
GM bil.
R0/1 cm Yes 18 mo No 1.8 yr/AWD
8 77/F 2011 Cryoblation - - - - - 1.9 yr/AWD
Dx, diagnosis; Rx, marginal status not defined; MDT, minimal distance from tumor; PA, posterior approach; CA, combined approach; AWD, alive with disease; DOD, dead 
of disease; AFD, alive free of disease; GM bil, gluteus maximus muscle; Piri. bil, piriformis muscle.
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primary resection. Four patients (#3, #5, #6, and #7) who had un-
dergone a preoperative diagnostic core-needle biopsy had pri-
mary surgery in our institution.
The patients operated elsewhere (#1, #2, and #4) all had R1 mar-
gins. They developed LR (or disease progression) at 24, 24, and 11 
months, respectively, and were operated on secondarily at our in-
stitution. Patient #4 had a reresection through a combined antero-
posterior approach with negative margins (R0). Of note is the fact 
that he presented a positive, clinically-enlarged external iliac 
lymph node on frozen section, so a radical ilio-obturator lymph-
node dissection was added. No further positive lymph-nodes 
were found. He had a local rerecurrence 2 years later. Patients #1 
and #2 were reoperated on by using a posterior approach only, 
and both had still positive margins (R1) and further loco-regional 
rerecurrence. Patient #1 underwent a third operation, a combined 
anteroposterior approach, with palliative intent. He received adju-
vant radiotherapy and imatinib mesylate therapy. He is currently 
alive with residual disease 14 years after the initial diagnosis. Re-
currences in patients #2 and #4 were treated with palliative radia-
tion therapy (RT), local radiofrequency ablation and imatinib 
mesylate therapy. Patient #2 died of disease 11 years after the pri-
mary diagnosis. Patient #4 is still alive with residual disease 4.7 
years after the initial diagnosis.
The four patients who were resected primarily in our hospital 
and who had a known preoperative diagnosis underwent en bloc 
surgery with R0 resection margins (Fig. 1). This radical surgery 
was performed in collaboration with orthopedic and spine sur-
geons. One patient (#3) underwent a posterior approach only 
with primary closure of the pelvic floor. The operative time was 5 
hours. The other three patients underwent a combined antero-
A B
C D
Fig. 1. (A) Clinical presentation of the sacral chordoma in patient #7. (B) Pelvic floor resection of asacral chordoma treated by using a com-
bined approach. (C, D) En bloc resection with skin and smooth perineal tissue, the sacrum and the rectum.
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posterior approach. Patient #5 had undergone neo-adjuvant ra-
diotherapy. Cumulative operative times (reconstructive surgery 
included) were 5, 18.5, and 15.5 hours for patients #5, #6, and #7, 
respectively. Three of the patients operated on primarily in our 
institution, patients #3, #5, and #6, remain disease-free with fol-
low-ups of 1.6, 2.9, and 8 years, respectively; patient #7, present-
ing with an initial 12.5-cm × 13-cm mass infiltrating the mesorec-
tum, developed LR and bilateral lung metastasis 18 months after 
surgery (Fig. 1).
Perineal wound closure and surgical morbidity
According to the extent of surgery and the need for vascularized 
tissue to fill the space after resection, different options were taken 
to close the perineal wound (Table 2). Direct wound closure was 
possible in four of the seven patients (#2, #3, #5, and #6), but three 
of them (#2, #5, and #6) developed wound dehiscence. In two 
cases, wounds healed by secondary intention. One patient (#5) 
was treated by using vacuum-assisted closure (VAC,  KCI Con-
cepts, San Antonio, TX, USA) during two months, and definitive 
repair was achieved with bilateral rotational gluteal flaps.
When direct closure was not feasible, four out of the seven pa-
tients, reconstruction with large flaps was performed by plastic 
surgeons. In two patients (#1 and #5), reconstruction was carried 
out with bilateral or single gluteal fasciocutaneous rotational flaps 
(operative times of 3 and 1.5 hours, respectively) during the same 
operation in patient #1 or after complete dehiscence of the pri-
mary closure in patient #5. For the other two patients (#4 and #7), 
due to a large perineal defect, we decided to wait for the final his-
tologic assessment of resection margins prior to definitive repair. 
The wound was temporarily closed with Vicryl mesh and VAC, 
and 15 and 21 days later, definitive reconstruction was achieved 
with a pediculated myocutaneous anterolateral thigh (ALT) flap 
including the vastus lateralis muscle to increase bulkiness and fill 
the dead space (operative times of 6.5 and 5 hours, respectively). 
In both cases, the fascia lata was included in the flap to reinforce 
the perineum. Three out of four patients who underwent recon-
structive procedures presented postoperative complications. Pa-
tient #1 presented with a caudal dehiscence one month after a flap 
procedure using a rotational fasciocutaneous flap based on infe-
rior gluteal perforators. Healing was achieved after debridement 
and refixation of the flap. Patient #5 developed a medial dehis-
cence between the two flaps, requiring debridement and direct 
closure one month after the reconstructive procedure. For patient 
#7, the flap presented a venous congestion at postoperative day 1 
due to excessive tension closure; a surgical re-exploration was re-
quired. The partial flap necrosis was debrided, and two further 
operations with mobilizations of the local gluteal fasciocutaneous 
flaps (three and four weeks postoperatively, respectively) were 
necessary to achieve definitive wound healing and closure. 
The overall morbidity rate was 86% (6/7 patients) and was 
mainly related to the perineal wound. A pelvic lymphocele was 
detected in 4/7 patients and an abdominal wall abscess in 2/5 pa-
tients who underwent a combined approach. Bladder dysfunction 
was observed in 3/7 patients, and erectile dysfunction in one of 
the four men. Two of the seven patients complained of chronic 
perineal pain. For patients operated on in our institution, the me-
dian hospital stay was 30 days (range, 7–184 days).
DISCUSSION
Our small series of patients treated for a sacral chordoma invad-
ing the perineum and adjacent visceral structures emphasizes the 
complexity of this type of surgical treatment. Our results confirm 
that chances to obtain an R0 resection are higher for patients who 
have an accurate preoperative diagnosis and who undergo an ag-
gressive multidisciplinary treatment rather than for patients who 
have been misdiagnosed and are in need of secondary surgery [3, 
4, 11, 13]. The quality of surgical margins at initial surgery is the 
primary prognostic factor for LR [7, 11, 12, 17-19], with the 10-
year OS rates ranging between 30% and 65% depending on the 
surgical margins [5, 7, 8-12]. A review of the recent literature 
shows LR rates ranging between 0% and 60% for wide margins, 
between 31% and 71% for marginal margins, and between 67% 
and 100% for intralesional resection margins (Table 3).
Sacral chordomas often present with nonspecific signs and 
symptoms, which can delay diagnosis. Indeed, the majority of 
Table 2. Reconstruction surgery and complications
No
Age/
gender
Last 
surgery
Resection
level
Immediate
procedure
Early
reconstruction
Wound
complication
Delayed
reconstruction
Time to 
complete healing
1 43/M CA S3 GF - Dehiscence No 2 mo
2 58/F PA S1–S2 DC No Dehiscence No 3 mo
3 62/M PA S3 DC No No No 3 wk
4 40/M CA S3 VAC ALT No No 1 mo
5 60/F CA S1–S2 DC No Dehiscence GF 5 mo
6 32/F CA S3 DC No Dehiscence No 5 mo
7 34/M CA S3 VAC ALT Necrosis GF 2 mo
CA, combined approach; PA, posterior approach; VAC, vacuum assisted closure system; GF, gluteus maximus flap; ALT, Antero-lateral thigh flap; DC, direct closure.
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sacral chordomas reported in the literature are proximal lesions at 
or above S3 (Table 3). In the absence of a preoperative diagnosis 
and a well-prepared multidisciplinary team, the risk of violating 
tumor margins is very high. A differential diagnosis for sacral 
chordomas includes pilonidal sinus disease, deep abscesses, rectal 
sarcomas, and several retrorectal tumors (teratomas, extraperito-
neal adenomucinosis, cystic lymphangiomas, neurogenic tumors 
and cysts, developmental tailgut cysts, sacral myelomeningocele, 
and rectal duplication) [20-22]. The typical clinical presentation 
for a sacral chordoma is a slow-growing palpable mass in the sa-
crum that is often painless, is without inflammatory or infectious 
signs, and is rarely associated with rectal dysfunction or urinary 
incontinence at the time of diagnosis. Unlike developmental cysts, 
chordomas almost never get infected or cause fistulization, but 
demonstrate bone destruction on radiological imaging, which is 
very uncommon with all other benign retrorectal lesions. Diag-
nosis is made by using CT and MRI, which are crucial to define 
the extent of the disease. On a CT scan, sacral chordomas show 
large lytic lesions centred in the midline and an associated soft-
tissue mass. Calcifications are present in 30%–70% of the cases. 
On MRI, sacral chordomas, compared with skeletal muscle, have 
an isointense or slightly hypointense signal on T1-weighted im-
ages and are typically hyper-intense on T2-weighted images [23] 
(Fig. 2). Core-needle biopsy by an experienced radiologist is man-
datory to obtain a definitive diagnosis and to adequately plan an 
extensive and debilitating surgery.
A B
C D
Fig. 2. (A) Pelvic computed tomography (CT) scan in the sagittal plane. Patient #3 presented with a 5.5-cm × 4-cm chordoma at the S3–S4 
level. (B) Pelvic CT scan in the sagittal plane. Patient #7 presented with a 12.5-cm × 13-cm mass infiltrating the mesorectum. (C) T-2 weighted 
pelvic magnetic resonance imaging (MRI) in the sagittal plane. Patient #6 presented with a chordoma at the S3–S4 level and with distal pro-
gression. (D) T-1 weighted pelvic MRI in the sagittal plane. Patient #5 presented with a chordoma at the S2 level and a pattern of infiltration 
towards deeper structures.
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The surgical strategy is best discussed at a multidisciplinary sar-
coma tumor board in order to plan an R0 resection. For proximal 
chordomas and/or for chordomas infiltrating the mesorectum, a 
combined approach offers a better visualization of the proximal 
border of the tumor in the pelvis and allows removal of the ano-
rectum en bloc with the sacral mass. For several authors, extension 
of the lesion above S3 is considered an obligation to perform a 
combined approach [3, 4, 7]. The risk of inadequate surgical mar-
gins is also related to the extension of the disease in the soft tissue. 
Hanna et al. [3] suggested that infiltration of the musculature adja-
cent to the sacrum and/or involvement of the sacroiliac joints in-
creases the tendency for LR, even after an apparently-successful en 
bloc resection. All patients with invasion of surrounding muscle 
had a higher recurrence rate (76.9%). Similarly, Chen et al. [13] 
showed that the presence of muscle invasion was a significant ad-
verse factor for disease-free survival (DFS). Such a clinical presen-
tation usually indicates an advanced stage and is frequently associ-
ated with progression, even when a R0 resection is performed, as 
for patient #7 of our series. Smaller and distal lesions can be re-
sected through a less invasive, posterior only approach [4, 24-27]. 
In our study, two patients (#1 and #2) with recurrence underwent 
a posterior approach only. These two patients radiologically had no 
sign of mesorectal infiltration and had an intact anorectum. How-
ever, in one patient, multiple pelvic implants that precluded an R0 
resection were discovered intraoperatively. In the second patient, 
the distinction between the tumour and healthy tissues was diffi-
cult to assess because of previous surgery and radiotherapy.
Bladder and bowel dysfunction, motor deficits, lymphatic com-
plications, pelvic hematomas, and cerebrospinal fluid fistulae are 
commonly reported in the literature as postoperative complica-
tions after resection of a sacral chordoma [7, 28-31]. As we ob-
served, wound dehiscence after a sacrectomy remains the most 
significant postoperative complication (25%–46%) [30, 31]. Chen 
et al. [3] found that albumin <3.0 g/dL, operating times >6 hours 
and previous surgery were statistically significant risk factors for 
wound infection after sacral tumor surgery.
Adjuvant treatment for a sacral chordoma remains controver-
sial. Chordomas are known to be radio-resistant to a standard 
dose of RT (≤60 Gray) [32, 33]. Surrounding structures like the 
bladder, small bowel and sacral plexus are radiosensitive and im-
pose limits to the extent of RT. Cheng et al. [14] described a possi-
ble beneficial effect of adjuvant RT on the DFS but not on the OS. 
Noel et al. [34] reported an 80.5% 5-year survival for 100 patients 
with a skull-base chordoma who were treated with high-dose RT 
(>60 Gray). Modern RT techniques, like intensity modulated ra-
diotherapy (IMRT), offer the possibility for an integrated boost 
concept with dose escalation while reducing the dose to organs at 
risk in proximity to the tumor due to a more conformal dose dis-
tribution. In the study of Zabel-du-Bois et al. [15], 34 patients 
with a sacral chordoma were treated with postoperative IMRT or 
with IMRT alone. Patients treated at the time of initial diagnosis 
showed a significant higher local control rate (47%) compared 
with patients treated with IMRT for recurrent disease (24%). Pa-
tients receiving >60 Gray had a significantly improved OS com-
pared with patients treated with ≤60 Gray (85% vs 43%, P < 0.01). 
Moojen et al. [11] in a series of 15 patients showed a benefit with 
RT (>50 Gray) after LR in terms of local control and OS. In 10 pa-
tients with a R0 resection who developed a LR, 6 had RT with a 
mean survival of 7 years, suggesting a possible benefit of RT for 
recurrent disease after radical surgery.
No studies have assessed the role of neo-adjuvant RT for treating 
a sacral chordoma. We decided to use this approach in one patient 
(#5) with extensive disease by analogy to a retroperitoneal sar-
coma. Preoperative RT may provide less gastrointestinal toxicity 
and better delineation of the tumor, with the possibility to obtain a 
sterilized surgical field and a pseudo-capsule around the tumor 
[35, 36]. Nevertheless, no decrease in tumor size was observed four 
weeks after the end of the neoadjuvant RT. Histopathology did not 
show any postradiation tumor necrosis or fibrosis.
No chemotherapy has proven any benefit in term of OS and lo-
cal control in patients with a chordoma. The advent of molecular-
targeted therapies has offered some encouraging alternatives for 
the management of advanced disease. Imatinib mesylate, associ-
ated with the cisplatine or the mechanistic target of rapamycin 
(mTOR) inhibitor, can be used in recurrent nonoperable or lo-
cally nontreatable chordomas and in metastatic disease [37, 38]. 
Stacchiotti et al. [39] described the use of imatinib mesylate in a 
phase II study of 56 patients with progressive disease. They dem-
onstrated a clinical benefit in 35 patients, but reduction in tumor 
size was observed in 9 only. Tamborini et al. [40] suggested that 
the clinical benefit observed in chordoma patients treated with 
imatinib mesylate was related to switching off PDGFRB, PDG-
FRA and Kit. Based on these results, we treated two of our pa-
tients with imatinib mesylate. One patient is still alive with resid-
ual disease 14 years after the primary diagnosis, and one patient 
died of disease after 11 years. Further studies are necessary to 
confirm the role of molecular-targeted therapy in an adjuvant set-
ting for sacral chordoma therapy.
Other treatment modalities for a sacral chordoma have been de-
scribed in the literature. Cryosurgery for bone tumors was first 
described by Marcove et al. [41]. Other authors have used it as an 
adjuvant therapy for sacral tumors including chordomas [42]. We 
performed cryosurgery in one patient with poor performance 
status for a sacral tumour of 4 cm × 3 cm. He is currently alive 
with residual disease two years after treatment. This could be an 
effective alternative for patients with a single well-defined lesion 
who are unfit for surgery.
Perineal reconstruction after radical extended resection for a 
sacral chordoma may become very complex and require the in-
volvement of plastic surgeons. The key point of reconstruction is 
to provide stable and vascularized soft-tissue coverage to fill dead 
spaces and a solid pelvic floor and to avoid deep infections in 
body areas particularly at risk of bacterial contamination [43]. 
The type of reconstruction depends on the size of the pelvic de-
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fect. Small sacral defects may be treated like pressure sores and re-
constructed by using muscular or fasciocutaneous gluteal flaps 
[43]. These are vascularized by superior or inferior gluteal arteries 
and can be designed as rotational flaps or advancement flaps in a 
V-Y shape [44, 45]. We used rotational fasciocutaneous gluteal 
flaps in two of our patients, for primary reconstruction in one and 
for complementary reconstruction in the other. When the resid-
ual empty space in the pelvis is too large, it must be filled with 
healthy tissue. In addition, the gluteal arteries vascularizing the 
gluteal flaps may have been sacrificed during oncologic resection. 
The transpelvic vertical rectus abdomini myocutaneous flap has 
been described for vaginal and pelvic reconstruction [43, 46]. It is 
usually avoided in patients who have undergone a laparotomy be-
cause of significant donor site morbidity, like fascial dehiscence, a 
hernia and an imbalance of truncal core muscular support [47, 
48]. Moreover, the muscle and skin paddle may be insufficient. 
Free flaps can be another choice, but access to recipient vessels at 
the wound site may be challenging [43]. Two of our patients pre-
sented huge defects requiring not only a large skin paddle but also 
a considerable amount of muscular tissue to fill the pelvic defect 
and to reconstruct the perineum. For these reasons, we used ALT 
flaps associated with the vastus lateralis muscle to create a com-
posite myocutaneous flap [43, 49]. This type of flap has a long 
vascular pedicle and a large skin paddle and can be raised with 
the muscolocutaneous perforators that feed the muscle part. 
Thanks to the long pedicle and to the big arc of rotation, the flap 
can be transferred to cover the posterior defect. Complication 
rates in perineal and sacral reconstructions of very large defects 
can exceed 50%, especially in association with high-dose RT, obe-
sity and diabetes [43], as encountered in our patient #5. Liver fail-
ure (patient #7) can increase operative risk by affecting tissue 
quality and wound healing [50].
Our study has several limitations. The number of patients in-
cluded was small because of the rarity of this disease, but these 
patients shared a common complex pelvic presentation. Further-
more, follow-up was short for the last three patients, who recently 
underwent surgery. We were unable to apply the Enneking classi-
fication [51] for musculoskeletal neoplasms, which is used by oth-
ers to report the resection status of a sacral chordoma, as the pa-
thologist seldom described a reactive tissue around the tumor 
pseudo-capsule, which represents the demarcation between a 
marginal and a wide resection margin. However, the R classifica-
tion is a strong indicator of prognosis and facilitates comparison 
of treatment results if applied in a constant manner [52].
In conclusion, despite the obvious limitations of our study, our 
results highlight the difficulty of obtaining clear margins with re-
done surgery because of initially-misdiagnosed chordomas. A 
primary R0 resection still remains the gold standard for the treat-
ment of this tumor, but is no guarantee of a cure, especially in pa-
tients with tumors extending into the musculature. Even in cor-
rectly-diagnosed patients treated in a tertiary center, a definitive 
cure of the disease remains difficult to obtain despite a multidisci-
plinary approach with modern adjuvant therapies. Reconstructive 
surgery may be challenging in these situations, and an ALT flap 
could be a good option in selected patients. Due to the rarity of 
the disease, randomized studies are unlikely to be performed, and 
creation of national prospective databases could help improve the 
prognosis for such patients.
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